Home › Multiple Myeloma › New Mexico
Pag-aaral pangklinika para sa Multiple Myeloma sa New Mexico
5 pag-aaral para sa Multiple Myeloma ang naghahanap ng mga kalahok sa mga site sa New Mexico.
Opisyal na teksto ng pag-aaral (English)
A Study Comparing JNJ-79635322 and Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma
- Christus St. Vincent Regional Cancer Center, Santa Fe
Nagre-recruitPhase 3
Edad 18 pataas · Lahat ng kasarian · Na-update Set 25, 2026 · NCT07518186A Study of Teclistamab in Combination With Daratumumab and Lenalidomide (Tec-DR) and Talquetamab in Combination With Daratumumab and Lenalidomide (Tal-DR) in Participants With Newly Diagnosed Multiple Myeloma
- Christus St. Vincent Regional Cancer Center, Santa Fe
Nagre-recruitPhase 3
Edad 18 pataas · Lahat ng kasarian · Na-update Set 25, 2026 · NCT05552222TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer
- Lovelace Medical Center - Saint Joseph Square, Albuquerque
- Presbyterian Kaseman Hospital, Albuquerque
- The University of New Mexico Comprehensive Cancer Center, Albuquerque
- at 2 pa
Nagre-recruitPhase 2
Edad 12 pataas · Lahat ng kasarian · Na-update Set 22, 2026 · NCT02693535A Study to Evaluate the Efficacy and Safety of Belantamab Mafodotin in Combination With Standard of Care in Participants With Relapsed-Refractory Multiple Myeloma (RRMM)
- GSK Investigational Site, Farmington
Nagre-recruitPhase 2
Edad 18 pataas · Lahat ng kasarian · Na-update Ago 25, 2026 · NCT07227311Comparing Combinations of Drugs to Treat Newly Diagnosed Multiple Myeloma (NDMM) When a Stem Cell Transplant is Not a Medically Suitable Treatment
- Lovelace Medical Center-Saint Joseph Square, Albuquerque
- University of New Mexico Cancer Center, Albuquerque
- Presbyterian Kaseman Hospital, Albuquerque
- at 1 pa
Nagre-recruitPhase 3
Lahat ng edad · Lahat ng kasarian · Na-update Hun 10, 2026 · NCT05561387Mula sa ClinicalTrials.gov, na-kuha noong Okt 5, 2026. Ang bawat pag-aaral ay may sariling pamantayan sa eligibility; ang koponan ng pag-aaral ang magdedesisyon kung sino ang makakasali.